Firm at a glance
F-Prime Capital is a platform private equity firm headquartered in Cambridge, MA, with approximately $5.3 billion in assets under management as of early 2026 [S1].
What they buy
F-Prime Capital’s public portfolio demonstrates a concentration in three primary areas: life sciences companies developing therapeutics and biologics, technology businesses serving enterprise and consumer markets, and healthtech service providers [S2]. The firm’s investment history spans early-stage venture through growth equity, with portfolio entries dating from 2011 through 2019 across these sectors [S2]. Notable investments include both publicly traded companies and private growth-stage businesses in biotechnology, software, and healthcare delivery [S2].
Portfolio
Life Sciences
Beam Therapeutics (2018), Semma Therapeutics (2014), Innovent Biologics (2011), Denali Therapeutics (2015), Adagene, Adaptimmune, Avalon GloboCare, Alloy Therapeutics, and Applied Therapeutics [S2].
Technology
Toast (2016), Flywire (2013), Duetto (2017), Benchling (2018), Acrisure, and Alibaba [S2].
Healthtech + Services
Equip (2019), Devoted Health (2017), PatientPing (2014), Iora Health (2011), and Bluebird Kids Health [S2].
Recent activity (last 24 months)
No recent public transactions were surfaced in available sources for the 24-month period ending January 2026.
How this firm fits a seller
F-Prime Capital operates with offices in Cambridge, London, and San Francisco, suggesting a transatlantic investment footprint [S1]. The firm’s portfolio composition indicates a focus on venture and growth equity rather than traditional buyouts, which may suit founders and management teams seeking capital partners rather than full exits. The concentration in life sciences and healthtech aligns with sellers in biotechnology, therapeutics development, and healthcare technology sectors. The firm’s historical investment dates suggest patient capital deployment across multi-year holding periods [S2].
Sources
[S1] https://fprimecapital.com/about/ (as of 2026-01-08)
[S2] https://fprimecapital.com/portfolio/ (as of 2026-01-08)
Frequently asked questions
Does F-Prime Capital buy Life Sciences businesses?
Yes, life sciences represents a substantial portion of F-Prime Capital’s public portfolio, with investments in companies including Beam Therapeutics, Denali Therapeutics, Innovent Biologics, and multiple other therapeutics and biologics developers [S2]. The firm’s portfolio includes both early-stage biotechnology ventures and more established life sciences platforms [S2].
What companies has F-Prime Capital acquired recently?
Public sources show portfolio companies including Toast (restaurant technology, 2016), Equip (healthtech services, 2019), and Beam Therapeutics (gene editing, 2018) among the firm’s investments [S2]. No transactions within the most recent 24-month period were identified in available public materials.
Where is F-Prime Capital based and how big is the firm?
F-Prime Capital maintains its headquarters in Cambridge, MA, with additional offices in London and San Francisco, CA [S1]. The firm reported approximately $5.3 billion in assets under management as of early 2026 [S1].
Is F-Prime Capital still actively acquiring?
Available public sources did not surface transactions within the trailing 24-month period ending January 2026. The firm’s website remains active and lists current portfolio holdings, though recent deal activity was not documented in the materials reviewed [S1][S2].
This profile is maintained by CT Acquisitions as an independent third-party reference. CT Acquisitions is not affiliated with, endorsed by, or a representative of the firm profiled. All facts sourced from publicly available materials as of the dates cited.